You are here: Industry Insights > Sosei

News List

Sosei, AbbVie sign drug discovery deal worth up to $1 billion expresspharma
June 28, 2020
The partnership will initially focus on the discovery of novel small molecules, targeting inflammatory and autoimmune diseases, the companies said in a news release.
Takeda, Sosei form gastrointestinal disease R&D pact fiercepharma
August 13, 2019
Takeda and Sosei Heptares have entered into a multitarget R&D agreement. Sosei is set to receive $26 million (€23 million) in upfront and near-term payments, plus up to $1.2 billion in milestones, to apply its GPCR expertise to targets of interest to Take
Sosei Heptares, Takeda Enter R&D Partnership contractpharma
August 06, 2019
Could be worth more than $1.2 billion and involves small molecules and biologics.
Sosei announces launch of COPD medication in biospectrumasia
March 25, 2019
Sosei Heptares announces that Ultibro® Breezhaler® and Seebri® Breezhaler® launched in China for the treatment of COPD
Sosei doses first patient with experimental neurodegenerative drug pharmatimes
December 14, 2018
Sosei has announced that the first healthy subject has been dosed with HTL0014242 - a novel small molecule being tested for its ability to slow neurodegeneration.
Shinichi Tamura re-takes CEO role at Sosei pharmaphorum
December 13, 2018
Sosei has announced that its founder and former CEO Shinichi Tamura will be re-taking the position of CEO as of next year.
Allergan, Sosei suspend clinical development of dementia drug pharmatimes
September 20, 2018
Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation...
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Anta biospace
March 14, 2018
Sosei Group Announces Global Rights from Teva Pharmaceutical Industries Limited ("Teva")